NANO Stock Overview
A clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Nanobiotix S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.60 |
| 52 Week High | €6.97 |
| 52 Week Low | €2.67 |
| Beta | 1.42 |
| 1 Month Change | 13.41% |
| 3 Month Change | 2.91% |
| 1 Year Change | -42.28% |
| 3 Year Change | -47.87% |
| 5 Year Change | -45.22% |
| Change since IPO | -41.90% |
Recent News & Updates
Some Confidence Is Lacking In Nanobiotix S.A. (EPA:NANO) As Shares Slide 26%
Nov 28
Nanobiotix S.A.'s (EPA:NANO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Jun 29Recent updates
Some Confidence Is Lacking In Nanobiotix S.A. (EPA:NANO) As Shares Slide 26%
Nov 28Nanobiotix S.A.'s (EPA:NANO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Jun 29Subdued Growth No Barrier To Nanobiotix S.A. (EPA:NANO) With Shares Advancing 26%
May 14We're Keeping An Eye On Nanobiotix's (EPA:NANO) Cash Burn Rate
Apr 26Is Nanobiotix (EPA:NANO) Weighed On By Its Debt Load?
May 11Nanobiotix (EPA:NANO) Has Debt But No Earnings; Should You Worry?
Dec 06Is Nanobiotix (EPA:NANO) Using Too Much Debt?
Jun 04How Should Investors React To Nanobiotix's (EPA:NANO) CEO Pay?
Dec 22
Shareholder Returns
| NANO | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -7.4% | 4.4% | -0.5% |
| 1Y | -42.3% | -18.0% | 0.6% |
Return vs Industry: NANO underperformed the French Biotechs industry which returned -17.2% over the past year.
Return vs Market: NANO underperformed the French Market which returned 0.7% over the past year.
Price Volatility
| NANO volatility | |
|---|---|
| NANO Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 10.1% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: NANO's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: NANO's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 110 | Laurent Levy | www.nanobiotix.com |
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.
Nanobiotix S.A. Fundamentals Summary
| NANO fundamental statistics | |
|---|---|
| Market cap | €170.75m |
| Earnings (TTM) | -€33.47m |
| Revenue (TTM) | €42.20m |
4.0x
P/S Ratio-5.1x
P/E RatioIs NANO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NANO income statement (TTM) | |
|---|---|
| Revenue | €42.20m |
| Cost of Revenue | €0 |
| Gross Profit | €42.20m |
| Other Expenses | €75.68m |
| Earnings | -€33.47m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | 100.00% |
| Net Profit Margin | -79.31% |
| Debt/Equity Ratio | -204.3% |
How did NANO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 07:23 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nanobiotix S.A. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mickael Chane-Du | Bryan Garnier & Co |
| Philippa Gardner | Edison Investment Research |
| Jonathan Miller | Evercore ISI |